© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Cross-regulation between the renin–angiotensin system and inflammatory mediators in cardiac hypertrophy and failure
aCardiology Section of the Department of Medicine, Winters Center for Heart Failure Research, Houston VAMC and Baylor College of Medicine, 6565 Fannin, MS 524, Houston, TX 77030, USA
bKlinik III für Innere Medizin der Universität zu Köln, Cologne, Germany
* Corresponding author. Tel.: +1-713-441-1252; fax: +1-713-441-1246. Email address: dmann{at}bcm.tmc.edu
One of the major conceptual advances in our understanding of the pathogenesis of heart failure has been the insight that heart failure may progress as the result of the sustained overexpression of biologically active "neurohormones", such as norepinephrine and angiotensin II, which by virtue of their deleterious effects are sufficient to contribute to disease progression by provoking worsening left ventricular (LV) remodeling and progressive LV dysfunction. Recently, a second class of biologically active molecules, termed cytokines, has also been identified in the setting of heart failure. Analogous to the situation with neurohormones, the overexpression of cytokines is sufficient to contribute to disease progression in heart failure phenotype. Although important interactions between proinflammatory cytokines and the adrenergic system have been recognized in the heart for over a decade, the nature of the important interactions between proinflammatory cytokines and the renin–angiotensin system has become apparent only recently. Accordingly, in the present review, we will discuss the evidence which suggests that there is a functionally significant cross-talk between neurohormonal and inflammatory cytokine signaling in cardiac hypertrophy and failure.
KEYWORDS Angiotensin II; Renin–angiotensin system; Heart failure; Tumor necrosis factor; Inflammation
Time for primary review 18 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1657 - 1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Vinik and D. Ziegler Diabetic Cardiovascular Autonomic Neuropathy Circulation, January 23, 2007; 115(3): 387 - 397. [Full Text] [PDF] |
||||
![]() |
J. F. Carroll, W. J. Zenebe, and T. B. Strange Cardiovascular Function in a Rat Model of Diet-Induced Obesity Hypertension, July 1, 2006; 48(1): 65 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishikimi, K. Tadokoro, K. Akimoto, Y. Mori, Y. Ishikawa, K. Ishimura, T. Horio, K. Kangawa, and H. Matsuoka Response of adrenomedullin system to cytokine in cardiac fibroblasts-role of adrenomedullin as an antifibrotic factor Cardiovasc Res, April 1, 2005; 66(1): 104 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-D. Schluter and K. C Wollert Synchronization and integration of multiple hypertrophic pathways in the heart Cardiovasc Res, August 15, 2004; 63(3): 367 - 372. [Full Text] [PDF] |
||||



